Pfizer, BioNTech reach deal with Covax for 40 million vaccine doses

SINGAPORE, Jan 24 (dpa): Pfizer and BioNTech announced an advance purchase agreement with Covax for up to 40 million doses of the Pfizer-BioNTech Covid-19 Vaccine.

Financial terms of the agreement were not disclosed.

The doses will be delivered throughout 2021.

The companies expect to deliver the first doses in the first quarter of 2021.

Covax is a global initiative coordinated by the Global Alliance for Vaccines and Immunization (GAVI), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to Covid-19 vaccines for all countries, regardless of income levels.

For the Covax Advanced Market Commitment 92 countries, the companies will provide the vaccine to Covax at a not-for-profit price, Pfizer and BioNTech said.

The Pfizer-BioNTech Covid-19 vaccine is authorized for use under an Emergency Use Authorization for active immunization to prevent coronavirus disease 2019 (Covid-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. - dpa
Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3

Pfizer , BioNTech , Agreement , 40 Million , Doses , Covac


Did you find this article insightful?


Next In Aseanplus News

Asean News Headlines as at 7pm on Wednesday (March 3)
Stop the repression, Pope Francis tells Myanmar junta
Myanmar police 'shoot protesters with little warning', killing at least nine
Two sessions to set bold economic vision for China
Miss Universe Thailand fired as mental health ambassador
Vietnam's Van Don International Airport reopens
Lack of Covid jab for kids will make family vacations to Thailand impossible: research
Indonesian security forces kill two suspected militants
China concerned about racial discrimination against Chinese in Australia: FM
Thai Cabinet okays MoU on expanding trade ties with Russia

Stories You'll Enjoy